Literature DB >> 10841540

Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma.

B P Klaholz1, A Mitschler, M Belema, C Zusi, D Moras.   

Abstract

The human retinoic acid receptor (hRAR) is a member of the nuclear receptor superfamily that regulates the transcription of target genes in a ligand-dependent manner. The three hRAR isotypes are targets for retinoids that are used in the treatment of various diseases, including breast cancer and skin diseases. Drug efficiency and safety depend on the pharmacological activity of enantiomers, which can differ because of the chiral environment generated by the target. We report the crystal structures of the hRARgamma ligand-binding domain bound to two enantiomers, the active BMS270394 and the inactive BMS270395, solved at 1.6 A and 1.7 A resolution, respectively. The crystal structures reveal that in both enantiomers, the hydroxyl moiety attached to the chiral center forms a hydrogen bond to the Met-272 sulfur atom, thus imposing a conformation of BMS270395 that differs significantly from that observed for BMS270394 and other known retinoids. BMS270395 adopts an energetically unfavorable conformation, accounting for its inactivity; in contrast, the conformation of BMS270394 is close to an energy minimum. Our high-resolution data allow rationalization of enantiomer discrimination by the receptor and provide a model system for the pharmacological properties of enantiomeric pairs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841540      PMCID: PMC18601          DOI: 10.1073/pnas.97.12.6322

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  A new model for protein stereospecificity.

Authors:  A D Mesecar; D E Koshland
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

2.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

3.  SHELXL: high-resolution refinement.

Authors:  G M Sheldrick; T R Schneider
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

4.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Authors:  J P Renaud; N Rochel; M Ruff; V Vivat; P Chambon; H Gronemeyer; D Moras
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

5.  Crystallography & NMR system: A new software suite for macromolecular structure determination.

Authors:  A T Brünger; P D Adams; G M Clore; W L DeLano; P Gros; R W Grosse-Kunstleve; J S Jiang; J Kuszewski; M Nilges; N S Pannu; R J Read; L M Rice; T Simonson; G L Warren
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1998-09-01

6.  Computational method for relative binding energies of enzyme-substrate complexes.

Authors:  T Zhang; D E Koshland
Journal:  Protein Sci       Date:  1996-02       Impact factor: 6.725

7.  Purification of the human RARgamma ligand-binding domain and crystallization of its complex with all-trans retinoic acid.

Authors:  N Rochel; J P Renaud; M Ruff; V Vivat; F Granger; D Bonnier; T Lerouge; P Chambon; H Gronemeyer; D Moras
Journal:  Biochem Biophys Res Commun       Date:  1997-01-13       Impact factor: 3.575

8.  Role of retinoic acid receptor gamma in the Rhino mouse and rabbit irritation models of retinoid activity.

Authors:  P R Reczek; J Ostrowski; K L Yu; S Chen; L Hammer; T Roalsvig; J E Starrett; J P Driscoll; G Whiting; P G Spinazze
Journal:  Skin Pharmacol       Date:  1995

9.  Retinoic acid receptor gamma mediates topical retinoid efficacy and irritation in animal models.

Authors:  S Chen; J Ostrowski; G Whiting; T Roalsvig; L Hammer; S J Currier; J Honeyman; B Kwasniewski; K L Yu; R Sterzycki
Journal:  J Invest Dermatol       Date:  1995-05       Impact factor: 8.551

Review 10.  Retinoids in cancer treatment.

Authors:  M S Tallman; P H Wiernik
Journal:  J Clin Pharmacol       Date:  1992-10       Impact factor: 3.126

View more
  13 in total

1.  Mass-spectrometric analysis of agonist-induced retinoic acid receptor gamma conformational change.

Authors:  Valerie J Peterson; Elisabeth Barofsky; Max L Deinzer; Marcia I Dawson; Kai-Chia Feng; Xiao-kun Zhang; Machender R Madduru; Mark Leid
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands.

Authors:  G Tocchini-Valentini; N Rochel; J M Wurtz; A Mitschler; D Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

3.  Stereospecificity of retinol saturase: absolute configuration, synthesis, and biological evaluation of dihydroretinoids.

Authors:  Alexander R Moise; Marta Domínguez; Susana Alvarez; Rosana Alvarez; Michael Schupp; Ana G Cristancho; Philip D Kiser; Angel R de Lera; Mitchell A Lazar; Krzysztof Palczewski
Journal:  J Am Chem Soc       Date:  2008-01-08       Impact factor: 15.419

4.  CONFIRM: connecting fragments found in receptor molecules.

Authors:  David C Thompson; R Aldrin Denny; Ramaswamy Nilakantan; Christine Humblet; Diane Joseph-McCarthy; Eric Feyfant
Journal:  J Comput Aided Mol Des       Date:  2008-07-09       Impact factor: 3.686

5.  Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold.

Authors:  Claudio Martínez; Michele Lieb; Susana Alvarez; Fátima Rodríguez-Barrios; Rosana Alvarez; Harshal Khanwalkar; Hinrich Gronemeyer; Angel R de Lera
Journal:  ACS Med Chem Lett       Date:  2014-03-19       Impact factor: 4.345

6.  Ligand-specific structural changes in the vitamin D receptor in solution.

Authors:  Kiran K Singarapu; Jinge Zhu; Marco Tonelli; Hongyu Rao; Fariba M Assadi-Porter; William M Westler; Hector F DeLuca; John L Markley
Journal:  Biochemistry       Date:  2011-12-05       Impact factor: 3.162

7.  Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.

Authors:  Pierre Germain; Sabrina Kammerer; Efrén Pérez; Carole Peluso-Iltis; David Tortolani; F Christopher Zusi; John Starrett; Philippe Lapointe; Jean-Paul Daris; Anne Marinier; Angel R de Lera; Natacha Rochel; Hinrich Gronemeyer
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

8.  An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity.

Authors:  Marcia I Dawson; Zebin Xia; Gang Liu; Mao Ye; Joseph A Fontana; Lulu Farhana; Bhamik B Patel; Sankari Arumugarajah; Mohammad Bhuiyan; Xiao-Kun Zhang; Young-Hoon Han; William B Stallcup; Jun-ichi Fukushi; Tomas Mustelin; Lutz Tautz; Ying Su; Danni L Harris; Nahid Waleh; Peter D Hobbs; Ling Jong; Wan-Ru Chao; Leonard J Schiff; Brahma P Sani
Journal:  J Med Chem       Date:  2007-05-10       Impact factor: 7.446

9.  Density functional and docking studies of retinoids for cancer treatment.

Authors:  Carlos H T P Silva; Paulo Almeida; Carlton A Taft
Journal:  J Mol Model       Date:  2003-11-22       Impact factor: 1.810

Review 10.  Retinoic acid actions through mammalian nuclear receptors.

Authors:  Pengxiang Huang; Vikas Chandra; Fraydoon Rastinejad
Journal:  Chem Rev       Date:  2013-12-05       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.